Do the antibodies made from the company Mederex cure cancer?
Question by M m: Do the antibodies made from the company Mederex cure cancer?
Do the antibodies made from the company Mederex cure cancer? Is this very promising to cure cancer?
In the year 2000, the stocks of Mederex was very high. I think now one share of their stocks is about 300 dollars. Why don’t you guys read the website of Mederex? They made antibodies from mice.
Corrected: In the year 2002, a share of the stock of Mederex was 300 dollars.
Best answer:
Answer by morningfoxnorth
If this was true, Mederex stock would be worth millions. There are many many different types of cancer.
Plus, how do you make antibodies from a company? Is there some magic formula you use on the buildings and desks?
Add your own answer in the comments!
JVZoo Product Feed
Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical
Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical
Article by Bharatbook
Bharatbook added a new report on ” Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical ” which gives an overview, Demand, Supply Trends and industry analysis reports.This report provides a comprehensive review of 27 candidate that are being evaluated for the treatment of ; covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 potential targets.
Globally, is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that -care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of on society drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required
Today, developments continue to be made in drug treatments for ; in chemotherapy, new drug combinations, and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new and therapeutic vaccines.
This Report
This report (see brochure) provides a comprehensive review of and reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating cancer alongside other cancers.
Today, more than 25 candidate therapeutic antibodies are in development or are being evaluated for the treatment of , most of which are already in clinical trials. This field is also showing substantial innovation and these molecules are being directed at 17 different targets. This report gives an overview of the status and clinical findings of these candidate vaccines, together with developmental and market-related perspectives in this field.
Key content:
• Late-stage (Phases 2/3, 3 and Approved, n = 4) pipeline and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) pipeline and companies• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting , Phase 1, 1/2 and 2• Drug targets being targeted by from preclinical through to Phase 3, and Approved• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of being evaluated for the treatment of • Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of being evaluated for the treatment of • Commercial partnerships and collaborations on pipeline therapeutic antibodies• Drug combination strategies in the evaluation of the targeting of • A comprehensive listing of salient details of clinical trials of being evaluated for the treatment of • Technical and market insights and perspectives in the development and clinical evaluation of the treatment of • Competitive and market-related information
Tables
• 1.1 Global incidence and mortality from lung cancer, 2008• 1.2 NSCLC survival rates, according to cancer stage• 1.3a Five-year relative cancer survival rates in the USA for white males• 1.3b Five-year relative cancer survival rates in the USA for white females• 1.4 US national expenditure on different cancers (2006)• 1.5 US lost productivity due to different cancer types in the US, 2005• 2.1 Approved/late-stage candidate the treatment of • 3.1 Early-stage being developed or evaluated for the treatment of lung cancer or for /other cancers• 4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or other cancers• 5.1 Approved/late-stage being developed for the treatment of lung cancer• 5.2 Early-stage candidate being developed or evaluated for the treatment of lung cancer or for other cancers• 5.3 Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for other cancers• 5.4 Approved/candidate the treatment of for lung cancer/other cancers• 5.5 Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for other cancers• 5.6 NSCLC survival rates, according to cancer stage
Figures
• 3.1 Early-stage pipeline therapeutic antibodies for the treatment of lung cancer or other cancers• 5.4 Approved and pipeline being developed or evaluated for the treatment of lung cancer or for lung/other cancers• 5.6 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer/other cancers• 5.10 Organisations developing or evaluating lung cancer therapeutic antibodies• 5.12 Clinical trials of the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=213744&rt=Lung-Cancer-Therapeutic-Antibodies-Pipeline-Strategies-and-Clinical.html
Or
Contact us at :
Bharat Book BureauTel: +91 22 27578668 / +91 22 27579438Fax: +91 22 27579131Email: info@bharatbook.comWebsite: http://www.bharatbook.com
About the Author
Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.
JVZoo Product Feed
Categories: Articles Tags: lung, strategies, antibodies, clinical , therapeutic, pipeline, cancer
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011
Article by Bharatbook
Bharatbook added a new report on ” Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011 ” which gives an overview, Demand, Supply Trends and industry analysis reports.This report provides a comprehensive review of 27 candidate therapeutic antibodies and 42 candidate vaccines that are being evaluated for the treatment of covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 targets, while the vaccines are directed at 24 antigens or antigen combinations.
Globally, the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of are driving the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing strategies, are urgently required. Today, advances continue to be made in drug treatments for chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy, in the development of new therapeutic antibodies and therapeutic vaccines.
This Report
This report provides a comprehensive review of lung cancer immunotherapy. With a focus on therapeutic vaccines and antibodies, it reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers. It provides a comprehensive review of pipeline developments, therapeutic strategies and clinical findings, covering therapeutic vaccines and antibodies.
Today, around 70 immunotherapies are being developed or evaluated for the treatment of lung cancer. This report reviews developments on 27 candidate therapeutic antibodies and 42 candidate vaccines for treating most of which are in clinical development.
The immunotherapy pipeline is showing substantial innovation and many new strategies are being evaluated. Today’s pipeline of therapeutic antibodies are directed at 17 drug targets. On the vaccine front, 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting vaccines have been treated as single targeting strategies.
More than 90% of the immunotherapy candidates in development or being evaluated for treating are identified in this report, are in clinical development. This report gives an overview of the status and clinical findings of these candidate therapies. It also gives developmental and market-related perspectives in this rapidly developing field.
Key content:
• Late-stage (Phases 2/3, 3 and Approved, n = 4) therapeutic antibodies and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) therapeutic antibodies and companies• Late-stage (Phases 2/3, 3 and Approved, n = 5) vaccines and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) vaccines and companies• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting hases 1, 1/2 and 2• Drug targets against which therapeutic antibodies are being directed, from preclinical through to Phase 3, and Approved• Antigen/antigen combinations being targeted by vaccines, from preclinical through to Phase 3, and Approved• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phases 1-3) of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of therapeutic antibodies being evaluated for the treatment of lung cancer• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of vaccines being evaluated for the treatment of lung cancer• Commercial partnerships and collaborations on pipeline therapeutic antibodies and vaccines• Drug combination strategies in the evaluation of therapeutic antibodies and vaccines for targeting• A comprehensive listing of salient details of clinical trials of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic antibodies and vaccines for the treatment of lung cancer• Competitive and market-related information
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=213740&rt=Lung-Cancer-Vaccines-and-Therapeutic-Antibodies-Pipeline-Strategies-and-Clinical-2011.html
Or
Contact us at :
Bharat Book BureauTel: +91 22 27578668 / +91 22 27579438Fax: +91 22 27579131Email: info@bharatbook.comWebsite: http://www.bharatbook.com
About the Author
Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.
Find More Survival Rate Lung Cancer Articles
JVZoo Product Feed
Categories: Articles Tags: lung, therapeutic, vaccines, pipeline, 2011 , clinical, antibodies, strategies, cancer
Attacking influenza: how human monoclonal antibodies neutralize the flu virus
This animation illustrates how directing monoclonal antibodies to the influenza virus prevents a conformational change in the protein that is necessary for viral entry into the host cell. Read more: www.dana-farber.org and see a video of Dr. Wayne Marasco of Dana-Farber Cancer Institute discussing this discovery.
JVZoo Product Feed
Categories: Videos Tags: influenza, neutralize, antibodies, human, virus, monoclonal, attacking
